ArticleBlood advances2018

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML.

Claire M Lucas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.